摘要
目的 探讨p63蛋白和生存survivin蛋白在弥漫大B细胞淋巴瘤中的表达及临床意义。方法采用免疫组化染色法检测p63蛋白、survivin蛋白及Ki-67在52例淋巴瘤（DLBCL）患者和10例反应性增生淋巴结石蜡标本中的表达。结果p63和survivin在DLBCL中表达阳性率分别为63．5％和76．9％。p63在反应性增生淋巴结呈阴性表达，survivin在反应性增生淋巴结中阳性率为20％，p63和survivin的表达在两组之间差异有统计学意义（P〈0．05）。在DLBCL中p63、survivin表达之间有相关性，二者的表达与Ki-67增值指数有相关性。p63、survivin阳性组复发率分别为68．0％和71．4％高于阴性组22．2％和30．8％。结论P63和survivin在DLBCL中异常表达，与DLBCL的增殖有关，二者表达是临床治疗和预后的不利因素。
Objective To investigate the expression and significance of 1963 and survivin in diffuse large B-cell lymphoma. Methods Immunohistoehemieal staining was used to detect the expression of p63, survivin and Ki-67 in the lymphnode tissues from DLBCL patients and lymph node reactive proliferation, Results The positive expression rate of p63 and survivin in DLBCL patients was 63.5% and 76. 9% respectively. 1963 was not expressed in lymph node reative proliferation. The positive expression rate of survivin in lymph node reative proliferation was 20%. The expression rates of survivin and p63 between two groups were significant difference. The expressions of p63 and survivin had relationships with Ki-67 LI. The relapse rate of groups with positive expression of survivin and p63 were higher than that of the negative groups. Conclusion The expression p63 and Survivin in DLBCL were abnormal and poor factors of therapy and prognosis. P63 and survivin may accelerate the proliferation of DLBCL.
出处
《中国临床实用医学》
2010年第11期92-93,共2页
China Clinical Practical Medicine
